Form 4: Vaxart CEO Steven Lo Sells Shares for Tax Obligations

Vaxart's President and CEO, Steven Lo, disposed of 22,425 common shares to cover tax obligations related to vested restricted stock units.

Summary

• Steven Lo, President, Chief Executive Officer, and Director of Vaxart, Inc. (VXRT), reported a transaction on March 18, 2026.
• Lo disposed of 22,425 shares of Vaxart Common Stock at a price of $0.6346 per share.
• This disposition was a 'withholding' transaction (Code F), meaning the shares were withheld by Vaxart to satisfy income tax obligations related to the net settlement of Restricted Stock Units (RSUs) that vested on the same date.
• Following this transaction, Steven Lo directly beneficially owns 2,611,634 shares of Common Stock.
• Additionally, 100,000 shares of Common Stock are indirectly beneficially owned by the Lo Family Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents the realization of executive compensation through RSU vesting, with the share disposition being a non-discretionary tax-related action rather than a sale driven by negative sentiment.

Positives

• Vesting of Restricted Stock Units (RSUs) for Steven Lo, indicating compensation realization.

Negatives

• Steven Lo's direct beneficial ownership of Vaxart common stock decreased by 22,425 shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. This specific filing indicates the vesting of executive compensation (RSUs) and the standard practice of withholding shares to cover tax liabilities, which is common across industries for equity-based compensation. It does not reflect a discretionary sale based on market sentiment.

Comparison to Industry Standards

• The practice of withholding shares for tax obligations upon RSU vesting is a standard industry practice for equity compensation plans across publicly traded companies, aligning with typical corporate governance and compensation structures.
• Many biotech and pharmaceutical companies, similar to Vaxart, utilize RSUs as a key component of executive compensation to align management incentives with shareholder value.

Related Party Transactions

• Steven Lo indirectly beneficially owns 100,000 shares through the Lo Family Trust.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by a key executive is minor and for tax purposes, unlikely to significantly impact shareholder confidence. The vesting of RSUs aligns executive incentives with shareholder value.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where Vaxart's CEO, Steven Lo, had shares withheld to cover tax obligations upon the vesting of Restricted Stock Units. Such transactions are common for executive compensation and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to warrant a change in investment stance, suggesting a 'hold' recommendation for existing positions.

Keywords

Vaxart, VXRT, Steven Lo, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Executive Compensation